scholarly journals Lopinavir/ritonavir treatment increases the placental transfer of bupivacaine enantiomers in human immunodeficiency virus-infected pregnant women

2018 ◽  
Vol 84 (10) ◽  
pp. 2415-2421 ◽  
Author(s):  
Rodrigo Metzker Pereira Ribeiro ◽  
Fernanda de Lima Moreira ◽  
Elaine Christine Dantas Moisés ◽  
Ricardo Carvalho Cavalli ◽  
Silvana Maria Quintana ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Pregnant Women ◽  
Placental Transfer ◽  
Immunodeficiency Virus

scholarly journals Maternal-Fetal Transfer and Amniotic Fluid Accumulation of Nucleoside Analogue Reverse Transcriptase Inhibitors in Human Immunodeficiency Virus-Infected Pregnant Women

2004 ◽  
Vol 48 (11) ◽  
pp. 4332-4336 ◽  
Author(s):  
Hélène Chappuy ◽  
Jean-Marc Tréluyer ◽  
Vincent Jullien ◽  
Jérôme Dimet ◽  
Elisabeth Rey ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Amniotic Fluid ◽  
Pregnant Women ◽  
Nucleoside Analogue ◽  
Placental Transfer ◽  
Plasma Samples ◽  
Reverse Transcriptase Inhibitors ◽  
Blood Samples ◽  
Immunodeficiency Virus ◽  
Glucuronide Metabolite

ABSTRACT This study was performed to investigate placental transfer of nucleoside analogue reverse transcriptase inhibitors (NRTIs) and their concentrations in amniotic fluid when given to human immunodeficiency virus (HIV)-infected pregnant women. A total of 100 HIV type 1-infected mothers receiving antiretroviral therapy, including one or more NRTIs, for clinical indications at the time of delivery were enrolled. Maternal blood samples and amniotic fluid were obtained during delivery or cesarean section, and paired cord blood samples were obtained by venipuncture immediately after delivery. Drug concentrations were measured by using high-performance liquid chromatography. A significant relationship between concentrations in maternal and cord plasma samples was found for zidovudine, lamivudine, stavudine, and didanosine. The ratio between the concentrations in cord and maternal plasma samples (R) was high for zidovudine (R = 1.22), its glucuronide metabolite (3′-azido-3′-deoxythymidine-β-d-glucuronide) (R = 1.01), stavudine (R = 1.32), lamivudine (R = 0.93), and abacavir (R = 1.03) and was low for didanosine (R = 0.38). The ratio between the concentrations in amniotic fluid and cord plasma samples was high for zidovudine (R = 2.24), its glucuronide metabolite (R = 2.83), stavudine (R = 4.87), and lamivudine (R = 3.99) and was lower for didanosine (R = 1.14). These findings indicate that most NRTIs cross the placenta by simple diffusion and are concentrated in the amniotic fluid, probably through fetal urinary excretion. The efficacy or toxicity of NRTIs may vary according to placental transfer.

scholarly journals Population Pharmacokinetics of Emtricitabine in Human Immunodeficiency Virus Type 1-Infected Pregnant Women and Their Neonates

2008 ◽  
Vol 53 (3) ◽  
pp. 1067-1073 ◽  
Author(s):  
Déborah Hirt ◽  
Saik Urien ◽  
Elisabeth Rey ◽  
Elise Arrivé ◽  
Didier K. Ekouévi ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Cord Blood ◽  
Pregnant Women ◽  
High Performance ◽  
Placental Transfer ◽  
Compartment Model ◽  
Effect Compartment ◽  
Maternal Circulation ◽  
Time Curve ◽  
Immunodeficiency Virus

ABSTRACT The objectives of this study were to evaluate emtricitabine (FTC) pharmacokinetics in pregnant women and their neonates and to determine the optimal prophylactic dose for neonates after birth to prevent mother-to-child transmission of human immunodeficiency virus (HIV). A total of 38 HIV-infected pregnant women were administered tenofovir disoproxyl fumarate (300 mg)-FTC (200 mg) tablets—two tablets at the initiation of labor and one daily for 7 days postpartum. By pair, 11 maternal, one cord blood, and two neonatal FTC concentrations were measured using a high-performance liquid chromatography-tandem mass spectrometry validated method and analyzed by a population approach. Model and mean estimates (interpatient variability) were a two-compartment model for mothers, with an absorption rate constant of 0.54 h−1 (61%), apparent elimination and intercompartmental clearances of 23.2 (17%) and 6.04 liters·h−1, and apparent central and peripheral volumes of 127 and 237 liters, respectively; an effect compartment linked to maternal circulation for cord blood and a neonatal compartment disconnected, after delivery, with a 10.6-h half-life (30%). After the 400-mg FTC administration, the median population area under the concentration-time curve and the minimal and maximal plasma FTC concentrations in pregnant women were 14.3 mg·liter−1·h and 1.68 and 0.076 mg/liter, respectively. At delivery, median (range) predicted maternal and cord blood FTC concentrations were, respectively, 1.16 (0.14 to 1.99) and 0.72 (0.05 to 1.19) mg·liter−1. We concluded that the 400-mg FTC administration in pregnant women produces higher exposition than does the 200-mg administration in other adults, at steady state. FTC was shown to have good placental transfer (80%). Administering 1 mg FTC/kg as soon as possible after birth or 2 mg/kg 12 h after birth should produce neonatal concentrations comparable to the concentrations observed in adults.

scholarly journals Elevated Levels of Estradiol in Human Immunodeficiency Virus–Infected Pregnant Women on Protease Inhibitor–Based Regimens

2017 ◽  
Vol 66 (3) ◽  
pp. 420-427 ◽  
Author(s):  
Kayode A Balogun ◽  
Monica S Guzman Lenis ◽  
Eszter Papp ◽  
Mona Loutfy ◽  
Mark H Yudin ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Protease Inhibitor ◽  
Pregnant Women ◽  
Immunodeficiency Virus

scholarly journals Social conditions and immune response in human immunodeficiency virus-seropositive pregnant women: a cross-sectional study in Brazil

2018 ◽  
Vol 51 (1) ◽  
pp. 21-29
Author(s):  
Aletheia Soares Sampaio ◽  
Ana Lucia Ribeiro de Vasconcelos ◽  
Clarice Neuenschwander Lins de Morais ◽  
George Tadeu Nunes Diniz ◽  
Anna Lígia de Castro Figueiredo ◽  
...  
Keyword(s):  
Immune Response ◽  
Human Immunodeficiency Virus ◽  
Pregnant Women ◽  
Cross Sectional Study ◽  
Social Conditions ◽  
Sectional Study ◽  
Cross Sectional ◽  
Immunodeficiency Virus

scholarly journals Prevalence of human immunodeficiency virus infection among primigravida, in Karnataka

2018 ◽  
Vol 5 (12) ◽  
pp. 5448
Author(s):  
Vani Srinivas ◽  
T. L. N. Prasad ◽  
Rajesh T. Patil ◽  
Sunil D. Khaparde
Keyword(s):  
Human Immunodeficiency Virus ◽  
General Population ◽  
Pregnant Women ◽  
Data Extraction ◽  
Demographic Data ◽  
Striking Difference ◽  
Hiv Status ◽  
Cross Sectional ◽  
Immunodeficiency Virus ◽  
The Difference

Background: Karnataka is one of the six high human immunodeficiency virus (HIV) prevalent states in India. We estimated prevalence among primigravida attending antenatal clinics in Karnataka, assuming this as a proxy for HIV incidence level in the general population.Methods: We tried estimating prevalence among primigravida using cross sectional samples. Data was collected in structured data extraction sheet for the month of September 2011, from all Integrated and Counselling tested Centres (ICTCs) of Karnataka. All the pregnant women were tested as per national protocol. We analysed the basic demographic data, geographical distribution including HIV status of spouse of primigravida.Results: In September 2011, 87580, pregnant women were tested and 238 (0.26%) were found HIV positive of which, 95 (40%) were primigravida. Prevalence among primigravida, was 0.3%. The prevalence among primigravida was highest in Bagalkot (1.6%) district. In Yadgir, Kodagu and Udupi the prevalence was zero. The high prevalent blocks were Jamakhandi, Mudhol, Gokak, Hospet and Muddebihal. 73.7% spouse of positive primigravida were tested for HIV and among those tested, 87.1% were found HIV positive.Conclusions: There is striking difference in the prevalence of HIV among primigravida in different districts of Karnataka probably indicates the difference in effectiveness of preventive interventions in these districts and within blocks. The preventive programs should be reached out to the labourer's and farmers in the general population to prevent the new infections in the general population.

Human immunodeficiency virus/acquired immunodeficiency syndrome in pregnant women

1992 ◽  
Vol 2 (6) ◽  
pp. 773-802 ◽  
Author(s):  
Sten H. Vermund ◽  
Miriam A. Galbraith ◽  
Susan C. Ebner ◽  
Amy R. Sheon ◽  
Richard A. Kaslow
Keyword(s):  
Human Immunodeficiency Virus ◽  
Pregnant Women ◽  
Acquired Immunodeficiency Syndrome ◽  
Immunodeficiency Virus ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome

scholarly journals Persistent Chlamydia trachomatis, Neisseria gonorrhoeae or Trichomonas vaginalis positivity after treatment among human immunodeficiency virus-infected pregnant women, South Africa

2020 ◽  
Vol 31 (4) ◽  
pp. 294-302 ◽  
Author(s):  
Andrew Medina-Marino ◽  
Maanda Mudau ◽  
Noah Kojima ◽  
Remco PH Peters ◽  
Ute D Feucht ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Antiretroviral Therapy ◽  
Chlamydia Trachomatis ◽  
Neisseria Gonorrhoeae ◽  
Antenatal Care ◽  
Pregnant Women ◽  
Trichomonas Vaginalis ◽  
Repeat Testing ◽  
Care Visit ◽  
Immunodeficiency Virus

The objective of this study is to assess the predictors and frequency of persistent sexually transmitted infection (STI) positivity in human immunodeficiency virus (HIV)-infected pregnant women treated for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) or Trichomonas vaginalis (TV) infection. We enrolled HIV-infected pregnant women attending their first antenatal care visit and tested them for urogenital CT, NG and TV infection using Xpert® CT/NG and TV assays (Cepheid, Sunnyvale, CA). Those testing positive were treated. Participants either notified partners to seek treatment or were given extra medication to deliver to partners for treatment. Repeat testing was conducted approximately 21 days post-treatment or treatment initiation. Among 427 participants, 172 (40.3%) tested positive for any STI. Of the 136 (79.1%) that returned for repeat testing, 36 (26.5%) tested positive for the same organism: CT = 27 (26.5%), NG = 1 (6.3%), TV = 11 (16.7%). Persistent CT positivity was independently associated with having more than one sex partner in the preceding 12 months (adjusted-prevalence ratio [aPR] = 3.03, 95% CI: 1.44–6.37) and being newly diagnosed with HIV infection during the first antenatal care visit compared to those currently on antiretroviral therapy (aPR = 3.97, 95% CI: 1.09–14.43). Persistent TV positivity was associated with not knowing if a partner sought treatment following STI disclosure (aPR = 12.6, 95% CI: 2.16–73.5) and prior diagnosis of HIV but not currently on antiretroviral therapy. (aPR = 4.14; 95% CI: 1.25–13.79). We identified a high proportion of HIV-infected pregnant women with persistent CT or TV positivity after treatment. To decrease the risk of re-infection, enhanced strategies for partner treatment programmes are needed to improve the effectiveness of STI screening and treatment in pregnancy. The relationship between not being on antiretroviral therapy and persistent STI positivity needs further study.

Sign in / Sign up

Export Citation Format

Share Document